RAD1901: Clinical Trials

10 trials of RAD1901, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 recruiting, 2 completed, 2 terminated, 1 not yet recruiting. 10 Phase 2, 5 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 210Recruiting 4, Completed 2, Terminated 2, Not yet recruiting 1, Withdrawn 1
Phase 15Recruiting 2, Completed 1, Terminated 1, Withdrawn 1

Follow RAD1901: new trials by email Literature Review of RAD1901 trials Research Report on RAD1901

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial Cancer
Biospecimen Collection, Computed Tomography, Elacestrant - Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma
Phase 2Not yet recruitingJonsson Comprehensive Cancer Center502026-12-182026-06-09
Ph 2 Elacestrant in ER Positive Uterine Sarcomas
Elacestrant - Uterine Sarcoma, Uterine Leiomyosarcoma
Phase 2RecruitingDana-Farber Cancer Institute302026-03-252026-05-22
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
Capecitabine, Elacestrant - Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer
Phase 2RecruitingKristina A. Fanucci2972026-01-162026-08-26
ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
Elacestrant, Trastuzumab Deruxtecan - Metastatic Breast Cancer, HER2 Low Breast Carcinoma
Phase 1 / Phase 2RecruitingKristina A. Fanucci652025-11-172026-06-10
A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer
Samuraciclib, Elacestrant Dihydrochloride - Metastatic Breast Cancer, Locally Advanced Breast Cancer
Phase 1 / Phase 2CompletedCarrick Therapeutics Limited492023-10-092026-03-23
A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer
Elacestrant, Onapristone - Breast Cancer
Phase 1 / Phase 2WithdrawnContext Therapeutics Inc.2023-06-012025-04-22
Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer
Elacestrant, Onapristone - Breast Cancer
Phase 1 / Phase 2TerminatedContext Therapeutics Inc.42022-12-022026-07-21
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Elacestrant, Abemaciclib - Breast Neoplasms, Brain Neoplasms
Phase 1 / Phase 2RecruitingStemline Therapeutics, Inc.732022-08-312026-10-09
Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms
RAD1901, Placebo - Vasomotor Symptoms, Hot Flashes
Phase 2TerminatedRadius Pharmaceuticals, Inc.1392015-12-012019-03-13
A Study to Evaluate the Effects of RAD1901 in the Treatment of Vasomotor Symptoms in Postmenopausal Women
RAD1901, Placebo - Hot Flashes
Phase 2CompletedRadius Pharmaceuticals, Inc.1002009-03-012018-09-26

Conditions studied

Breast Neoplasms (6)  ·  Hot Flashes (2)  ·  Adenosarcoma of the uterus (1)  ·  Brain Diseases (1)  ·  Brain Neoplasms (1)  ·  Breast Diseases (1)  ·  Central Nervous System Diseases (1)  ·  Central Nervous System Neoplasms (1)  ·  Endometrial Neoplasms (1)  ·  Neoplasms (1)  ·  Neoplasms by Site (1)  ·  Perivascular Epithelioid Cell Neoplasms (1)  ·  Sarcoma, Endometrial Stromal (1)

Sponsors

Context Therapeutics Inc. (2)  ·  Kristina A. Fanucci (2)  ·  Radius Pharmaceuticals, Inc. (2)  ·  Carrick Therapeutics Limited (1)  ·  Dana-Farber Cancer Institute (1)  ·  Jonsson Comprehensive Cancer Center (1)  ·  Stemline Therapeutics, Inc. (1)

Countries

United States (10)  ·  France (2)  ·  Spain (2)  ·  United Kingdom (2)  ·  Belgium (1)  ·  Germany (1)  ·  Greece (1)  ·  Italy (1)  ·  South Korea (1)  ·  Turkey (Türkiye) (1)

Top investigators

Kristina Fanucci, MD (2)  ·  Jordyn Silverstein, MD (1)  ·  Suzanne George, MD (1)

Results publications

PMID 27575546

NIH funding

2023 (1)